Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B immune globulin + antiviral therapy
- Development stage
- Unknown
- Lead developer
- Grifols
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
This is a combination therapy consisting of **hepatitis B immune globulin (HBIG)** and an **antiviral agent** (commonly lamivudine or adefovir)[1][2]. HBIG is a sterile solution of human immunoglobulin G containing high titers of antibody to hepatitis B surface antigen, providing passive immunity by neutralizing circulating HBV and protecting hepatocytes from infection[2][3][4]. The antiviral component (e.g., lamivudine, adefovir) is a small molecule that inhibits HBV DNA replication by targeting viral reverse transcriptase/DNA polymerase, thus reducing viral load and preventing resistance and recurrence[1][2]. This combination is primarily indicated for the **prevention of hepatitis B recurrence after liver transplantation** in patients with chronic HBV infection[1][2].
- Other names
- HBIG + antiviral therapyHBIG + lamivudineHBIG + adefovirhepatitis B immune globulin + lamivudine
02
Targets
HBsAg (Hepatitis B surface antigen)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on hepatitis B immune globulin + antiviral therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B immune globulin + antiviral therapy.